Preventing Pulmonary Embolism and Stroke: A New Era of Enhanced DOAC Efficacy and Safety

Date: Monday, Nov. 13
Time: 7:30-9 p.m.
Sponsored by Medscape Education and NATF (North American Thrombosis Forum)
Supported by Portola Pharmaceuticals, Inc.
Location: Anaheim Marriott, Grand Ballroom E and F
Address: 700 W. Convention Way

Pulmonary embolism remains a major cause of morbidity and mortality in patients both while in the hospital and in the early postdischarge period. The options for thromboprophylaxis have increased since the advent of the direct oral anticoagulants (DOACs). Dr. Samuel Goldhaber and a panel of experts will explore strategies designed to optimize prevention of both pulmonary embolism and stroke in at-risk patients. They will discuss best practices to manage anticoagulation-associated bleeding, as well as best practices to reduce the risk of rehospitalization in at-risk patients. This interactive session will close with a case-based panel discussion incorporating pearls for practice based on the latest evidence.

This content is provided as information only and does not reflect the opinions of the AHA, nor does AHA review or approve the programming. These events are not part of the official AHA Scientific Sessions 2017 as planned by the AHA Committee on Scientific Sessions Programming. These events are part of the unofficial symposia offered concurrently with Scientific Sessions.